NXN 462

Drug Profile

NXN 462

Alternative Names: NXN-462

Latest Information Update: 09 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeurAxon
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action Nitric oxide synthase type I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postherpetic neuralgia
  • Phase I Migraine

Most Recent Events

  • 09 Feb 2016 Phase-II development for Postherpetic neuralgia is ongoing in Canada
  • 09 Feb 2016 No recent reports on development identified - Phase-II for Postherpetic neuralgia in USA (PO)
  • 01 Jan 2015 NXN 462 licensed to Knight Therapeutics for commercialisation in Canada, Israel, South Africa and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top